UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant To Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report: June 9, 2015
(Date of earliest event reported)

COHBAR, INC.

(Exact name of registrant as specified in its charter)

Delaware	000-55334	26-1299952
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

1455 Adams Drive, Suite 2050
Menlo Park, CA 94025
(Address of principal executive offices and zip code)

(415) 388-2222
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

COHBAR, INC.
FORM 8-K

Item 7.01 Regulation FD Disclosure

On June 9, 2015, CohBar, Inc. (the "Company") posted a presentation titled, "CohBar Annual Shareholder Presentation" on its website, www.cohbar.com, under the heading "Investor Relations." The presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The presentation will be delivered to stockholders in attendance at the Company's 2015 Annual Meeting of Stockholders (the "Annual Meeting") on June 9, 2015. The Annual Meeting will be a virtual meeting, conducted via live webcast on the Internet. The presentation provides an overview of the Company's strategy, research and future objectives.

The information in this Item 7.01 and in the exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as otherwise expressly stated in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

The following exhibit is furnished herewith and this list is intended to constitute the exhibit index:

99.1 "CohBar Annual Shareholder Presentation," dated June 9, 2015.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

COHBAR, INC.
(Registrant)

June 9, 2015
(Date)

By: /s/ Jeffrey F. Biunno
Jeffrey F. Biunno
Chief Financial Officer

CohBar Annual Shareholder Presentation

June 9th, 2015

Legal Disclaimer

This presentation includes forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future plans, intentions, expectations, business prospects and opportunities. Examples of such forward-looking statements include: statements regarding our research plans and timelines, anticipated outcomes and timing of our research programs, IND-enabling activities and pre-clinical and clinical trials for our MBTs; expectations regarding the future market for any drug we may develop; expectations regarding the growth of MBTs as a significant future class of drug products; statements regarding the anticipated therapeutic properties of our MBTs and expectations regarding our ability to effectively protect and expand our intellectual property. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include: unanticipated difficulties or unfavorable results encountered in our research and development programs; our ability to raise additional capital when necessary to continue our operations and complete our research and development programs; our ability to recruit and retain key scientific personnel; and our ability to establish and maintain partnerships with research and industry partners. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, including the "Risk Factors" set forth in our Annual Report on Form 10-K, as supplemented by our quarterly reports on Form 10-Q. The forward-looking statements and other information contained in this presentation are made as of the date hereof and CohBar, Inc. does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Overview

- CohBar: Increasing healthy life span
  - Albion Fitzgerald - Chairman
- CohBar's groundbreaking discoveries
  - Hassy Cohen, MD - Founder
- CohBar's path to the clinic: from discovery to therapeutic
  - Ken Cundy, PhD - CSO
- CohBar's Science team, Strategy and Progress to date
  - Jon Stern - CEO
- Biotech Industry Valuation Perspectives
  - Albion Fitzgerald
- Q&A

CohBar – Breakthrough science to increase healthy life span

- **Our founders have been doing groundbreaking work for the past 15+ years** in the intersecting areas of geriatrics, metabolism, genetics, and biology
- **resulting in breakthrough discoveries about mitochondria**, the powerhouses of human cells, and the roles that mitochondria play in human metabolism and disease as we age.

- We believe these discoveries are the foundation for **an entire new class of mitochondrial-based therapeutic (MBT) drugs**, with potential to significantly slow the progression of major diseases associated with aging, **and increase healthy life span.**

- **We have assembled a leading team** of founders and advisors, together with drug development expertise and capabilities, to exploit these discoveries
- **and have built a pipeline of MBT drug candidates** which we are currently optimizing and targeting for pre-clinical and clinical activities over the next 2-3 years.

Lifespan vs. Healthspan
Years of Health vs. Disease



Graph ©Mark Collins-Glenn Foundation

Mortality from non-communicable diseases of aging has increased along with increased longevity



Source: NIH

Age and age-related diseases

Non-communicable Diseases
A global epidemic and enormous economic burden

- The four main non-communicable diseases — cardiovascular diseases, diabetes, cancers and chronic respiratory diseases — are now becoming a global epidemic. (WHO 2011)

- By 2030, non-communicable diseases are projected to cause nearly five times as many deaths as communicable diseases worldwide. (WHO 2011)

- Over the next 20 years, non-communicable diseases are expected to cost the global economy more than $30 trillion. (Harvard study)

Most major non-communicable diseases have age as a significant risk factor!

From a Groundbreaking Study by Dr. Nir Barzilai:
Centenarians and Offspring Have Lower Prevalence of Diseases

- 1 in 10,000 lives to 100 years old
- **Centenarians** have less or similar prevalence of diseases compared to **people who are 20 to 30 years younger.**
- Centenarian later-life and end-of-life medical costs are significantly lower
- Not attributable to lifestyle!
- Centenarian **offspring** have less prevalence of diseases compared to their age group. (A genetic factor?)
- Minor cell-nucleus DNA differences:
  Centenarians and offspring vs. control

Disease Prevalence within Population



- *Significant difference in mitochondrial behavior for centenarians and offspring*

Mitochondria – produce the energy inside cells
and have their own DNA

Core component of metabolism

Mitochondrial function declines with age/damage

Metabolic dysfunction with mitochondrial impairment is a significant aspect of major age-related diseases:

- **Diabetes, cardiovascular diseases**
- **Neurodegeneration, Alzheimer's**
- **Recognized as a contributing factor in cancer**

Until recently, scientists believed the mitochondrial genome contained only 37 genes.



Breakthrough research by our founders has revealed that the mitochondrial genome has as many as dozens of additional genes that encode peptides. These peptides, which we refer to as Mitochondria Derived Peptides, or "MDPs," influence metabolic activities by acting as messengers between cells.

Growing recognition of the significance of mitochondria in disease and aging



TheScientist
EXPLORING LIFE, INSPIRING INNOVATION

First fix for mitochondrial diseases

Researchers replace defective mitochondrial genomes with healthy ones in monkey embryos—a technique that could be used to prevent children from inheriting a variety of incurable genetic diseases caused by defective mitochondrial genes.

science 2.0
JOIN THE REVOLUTION

Mitochondrial Link Between High Glucose And Metabolic Disease

The New York Times

Global Diabetes Rates Are Rising as Obesity Spreads JUNE 8, 2015

And of our founders, which include three of the world's leading experts in the biology of aging and mitochondrial science



The New York Times

A CONVERSATION WITH/Nir Barzilai: It's Not the Yogurt: Looking for Longevity Genes

Cell Metabolism

Home Online Now Current Issue Archive Journal Information For Authors

The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance
C. Lee and P. Cohen

Time's 100 Most Influential People
David Sinclair. PhD (Harvard Medical School)

Mitochondria increasingly targeted by biotech: CohBar's unique approach optimizes mitochondrial-derived peptides to develop multiple mitochondria-based therapeutics

Mitochondria-targeted therapeutics:

Create new small molecules and biologics to repair defective or damaged mitochondria and restore functionality

Mitochondria-based therapeutics:

CohBar's approach: Find the drugs within the mitochondria to treat the disease



Mitochondria derived Peptides

Optimized peptides

MBTs treat the diseases directly

Mitochondria-based Therapeutics

Disease-targeted therapeutics:

Majority of existing drugs



CohBar Founder – Dr. Pincus "Hassy" Cohen

- **Dean of the Davis School of Gerontology, University of Southern California**
  - Executive Director of the Ethel Percy Andrus Gerontology Center
  - William and Sylvia Kugel Dean's Chair in Gerontology
  - MD degree from the Technion Israel Institute of Technology, Postdoctoral at Stanford University

- **Award-winning Research:**
  - Recipient of numerous awards for research, including the *National Institute of Aging "EUREKA"-Award,* the *NIH-Director-Transformative RO1-Grant* and the *Glenn Award for Research in Biological Mechanisms of Aging*

Drs. Cohen and Barzilai's combined research efforts related to aging and MDPs have been supported by over $30 Million of grant funding to their academic institutions

MDPs – A New Untapped Field in Biology

MDP's are a diverse and largely unexplored collection of peptides which has the potential to lead to novel therapeutics for a number of diseases with significant unmet medical needs.

MDP Biological Effects:

- MDPs influence cellular activities by acting as messengers between cells, triggering intra-cellular changes

- MDPs have metabolic effects, neuro-protective effects, cyto-protective effects and anti-inflammatory effects

- Humanin, the first MDP discovered in 2001 by Dr. Cohen (CohBar co-founder) and others, has protective effects in various animal disease models, including Alzheimer's disease, atherosclerosis, myocardial and cerebral ischemia, and Type 2 Diabetes

- The latest MDP, MOTS-c, discovered by Lee and Cohen at USC, was recently published and has potent effects on obesity and metabolism

MOTS-c plays a significant role in regulation of metabolism

Potential source of MBTs to treat Type 2 Diabetes, obesity, and fatty liver.



MOTS-c prevents weight gain in mice on a high fat diet



The Company plans to advance research on MOTS-c and novel MBT analogs of MOTS-c as our lead program, which we believe has the potential to lead to a commercially successful drug for the treatment of type 2 diabetes, obesity, and other indications.

MOTS-c - A Key Regulator of Metabolism



MOTS-c, a key regulator of metabolism, shows proof of principle in obesity model

Graphical Abstract



Cell Metabolism

The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance

Changhan Lee, Jennifer Zeng, Brian G. Drew, Tamer Sallam, Alejandro Martin-Montalvo, Junxiang Wan, Su-Jeong Kim, Hemal Mehta, Andrea L. Hevener, Rafael de Cabo, Pinchas Cohen

"MOTS-c, a new mitochondrial-derived peptide hormone that prevents obesity caused by a high-fat diet and stimulates the metabolism in the same way as exercise."

MOTS-c reverses age-dependent insulin resistance, inhibits human prostate/breast tumor growth in mice



MOTS-c reverses age-dependent insulin resistance in mice



MOTS-c inhibits human prostate and breast tumor growth in mice

SHLP-6 suppresses cancer progression in mice
Potential MBTs to treat prostate and breast cancer

The Company plans to advance its research on SLHP-6 and novel MBT analogs of SHLP-6 with the potential for the treatment of cancer.

SHLP-6

↓

Cancer



SHLP-6 slows tumor growth by killing cancer cells and reducing their blood supply

SHLP-2 protects neuronal cells from toxicity in vitro
Potential MBT for the treatment of Alzheimer's disease.





Humanin - effective in animal models of atherosclerosis, Type 2 Diabetes, neurodegeneration

Potential MBT to treat a variety of diseases





Exceptional Health and Humanin

The development of assays to measure humanin levels in plasma enabled the observation of humanin levels in aged patients and patients with poor endothelial function associated with cardiovascular diseases.

- Humanin declines with age but is higher in offspring of centenarians when compared to an age and gender matched control group.
- Humanin is lower in humans with poor endothelial function, a major risk factor for cardiovascular diseases.
- Humanin improves healthspan and lifespan in several animal models (worms to mice)
- Humanin acts as a dietary-mimetic hormone

Offspring with Familial Exceptional Longevity



Humans with Normal Endothelial Function



The Expanded Mitochondrial Genome

Many potential new regulatory peptides (MDP's)



CohBar CSO: Kenneth Cundy, PhD

Taking the discoveries to the clinic

- Joined CohBar in November 2014 as Chief Scientific Officer (CSO)
  - CSO and SVP for Xenoport, Inc. (NASDAQ:XNPT), Gilead Sciences, Sterling Drug
  - Ph.D. in pharmaceutical sciences from University of Kentucky
  - Patents/Publications: 46 US Patents, +100 International Patents, 77 Publications

- Highly experienced and successful drug development scientist/leader
  - FDA Applications: 15 INDs, 6 NDAs
  - Drugs Developed: 15 - including Hepsera, Tamiflu, Viread, Horizant, etc
  - Marketed Drugs Invented:
    - Tenofovir DF for HIV (Viread, Truvada, Atripla), sold over $30B
    - Horizant for Shingles and RLS
  - Invented Nanocrystals technology - used in numerous marketed drugs

CohBar's Preclinical Plan

Selection of an MBT drug candidate:

- Evaluation of existing MDPs and any newly discovered MDPs
- Determination of initial activity in efficacy models
- Prioritization of potential lead molecules
- Synthesis of new analogs (MBTs)
- Iterative evaluation of stability, pharmacokinetics, and efficacy
- Selection of an MBT candidate for IND-enabling activities

Completion of IND-enabling activities:

- Preclinical testing (toxicology, safety pharmacology, genetic toxicity, pharmacokinetics)
- GMP manufacturing and stability of drug substance and formulation
- Filing and clearance of an Investigational New Drug (IND) application with the FDA to allow subsequent clinical trials

MDP Optimization and Development into Mitochondria-Based Therapeutics (MBTs)

CohBar MBT Optimization Process:

- Synthesis of analogs of native MDP
- Physicochemical Properties
  - Solubility
  - Chemical stability
- Resistance to Enzymatic Degradation
  - Stability in tissues
- Efficacy
  - In vitro cell-based assays
  - In vivo disease models
- Pharmacokinetics
  - Half-life, distribution, elimination



Criteria for Selection of Drug Targets

Identify a target indication with:

- Preclinical evidence of activity for a CohBar MBT
- Large established market with potential for growth
- Unmet need that can be addressed by CohBar MBTs
- Potential for differentiation from current therapies
- Proven acceptance of injectable products
- Established regulatory path to approval
- Validated preclinical models
- Objective clinical endpoints
- Proven potential for early stage partnering
- Clear and defensible CohBar IP protection

CohBar – Global Therapeutic Market Opportunities



Source: Evaluate Pharma, 2014

CohBar R&D Resources



The CohBar Pipeline

MDP	Potential Indications	Stage	Observed Effects
MOTS-c	Type 2 Diabetes Obesity Fatty Liver Cancer & Proliferative Diseases	Preclinical	Anti-diabetic, insulin sensitizer, prevents obesity and fatty-liver in mice Inhibits prostate cancer growth, (pro-apoptotic, anti-angiogenesis) in mice
SHLP-6	Cancer & Proliferative Diseases	Preclinical	Anti-tumor (prostate and breast) activity, promotes autophagy Inhibits prostrate tumor growth in mice, induces apoptosis in breast, ovarian and liver
SHLP-2	Alzheimer's Disease Type 2 Diabetes	Preclinical	Neuroprotective factor and insulin sensitizer
Humanin Analogs	Cardiovascular Disease & Diabetes	Preclinical	Cytoprotective factor and insulin sensitizer

Projected Development Timeline and Milestones



CohBar CEO - Jon Stern
Building CohBar's Infrastructure

- **Started working with the company in 2012**
  - Senior business executive, over 30 years of diversified management experience
  - Early stage companies - CEO and Founder of Cine Coasters, Inc
  - B.S. in Business Administration from The University of California, Berkeley
  - MBA from Marshall School of Business at the University of Southern California

- **Evolving/expanding Leadership Role:**
  - Advisor -> Strategy and Financing -> Executive leadership
  - Establish business/scientific foundation, lead private/public financings

- **We will expand our leadership team with an industry-experienced CEO**
  - Develop strategic relationships within industry and the investment community

- **Jon will continue in a leadership role**

Significant progress over the past year

- Building the Team
  - Enhanced scientific leadership with the addition of Kenneth Cundy, Ph.D., Chief Scientific Officer and Kent Grindstaff, Ph.D., VP Biology
  - Opened new modern laboratory in Menlo Park, CA (Silicon Valley)
- Developing the Network
  - Completed agreements, engaged in research studies with University of Southern California, Albert Einstein College of Medicine and the University of Cincinnati
  - Expanded our Scientific Advisory Board and consultants
- Securing the Assets
  - Strengthened protection for our IP portfolio of licensed mitochondrial peptides with 2 issued patents and 2 patent applications, U.S. and International
- Obtaining Funding
  - Began reporting to the SEC as a public company in the U.S. and to SEDAR in Canada
  - Raised approximately $17 million through an IPO and private placements to fund expanded research and development activities
  - Listed in Canada on the Toronto Venture Exchange ("COB.U") and in U.S. on the OTCQX ("CWBR")

Strategy going forward

- Advance to the Clinic
  - Select lead MDP and allocate majority of resources toward its development
  - Initiate clinical evaluation of our first MBT candidate within 2-3 years
- Expand and Exploit our Network
  - Grow our team of advisors and research partners
  - Develop relationships/partnerships with pharmaceutical companies
- Own the MBT space
  - Continue to leverage our expertise in MDP discovery to expand our pipeline of research peptides
  - Expand our IP portfolio and protect our drug candidates with solid IP strategy including licensing and blocking IP
- Fund our Growth
  - Expand and develop our interaction with the investment community
  - Raise additional capital from existing warrants and future financings, to continue advancing the MBT pipeline

CohBar's Co-Founders, SAB & Consultants

David Sinclair, Ph.D.
Harvard Medical School
Sirtris Pharmaceuticals
Genocea

Amir Lerman, M.D.
Mayo Clinic
Stealth BioTherapeutics

David Lee, Ph.D.
USC, UCLA

Ronald Kahn, M.D.
Harvard Medical School
Joslin Diabetes Center



John Amatruda, M.D.
Merck
Bayer

Frank Calzone, Ph.D.
Amgen
REMD BioTherapeutics

Nick Livingston. Ph.D.
GSK, Bayer
NovaTarg Therapeutics

Paul Aisen, M.D.
UC San Diego
NeuroPhage

CohBar's Independent Directors

Life Sciences, early-stage and public company experience

Marc Goldberg – independent Director since November 2014

- Managing Director at BioVentures Investors (life science focused venture and private equity investment firm)
- Founding President of Massachusetts Biotechnology Council in 1985
- Previously a director of Enanta Pharmaceuticals (NASDAQ: ENTA)
- AB (Harvard), JD (Harvard Law School) and MBA (Harvard Business School)

Albion Fitzgerald –independent Director since May 2014

- Formerly Chairman and CEO of three early stage technology companies, including Novadigm, Inc (NASDAQ: NVDM)

Biotech Industry Risk/Return Model



Sample Early-stage Drug Discovery Company Valuations

Company	Disease	Date	Preclinical Market Cap	Market Cap Today	Percent Increase
Alnylam	Various	2010	$700m	$11,700m	1,500%
Verastem	Cancer	2012 IPO	$224m	$317m	40%
Agios Pharma	Cancer	2013 IPO	$942m	$4,570m	385%
Bluebird	Various	2013 IPO	$600m	$6,230m	938%
Epizyme	Cancer	2013 IPO	$90m	$798m	786%
Blueprint Medicines	Cancer	2015 IPO	$450m	$749m	66%

Potential Value Drivers Going Forward

CohBar Science and Pipeline:

- Pre-clinical data and publications on CohBar drugs
- Advancement of lead program into human trials
- Additional IP in the mitochondria space

Industry Awareness and Relationships:

- Recognition as leader in mitochondria and aging
- Interest from the Pharma industry in CohBar's IP assets and drugs
- Potential partnerships with Pharma

Market Awareness and Positioning

- Expanding shareholder base in U.S. financial markets
- Leverage leadership with top-tier biotech investors

CohBar – Breakthrough science to increase healthy life span

- **Our founders have been doing groundbreaking work for the past 15+ years** in the intersecting areas of geriatrics, metabolism, genetics, and biology
- **resulting in breakthrough discoveries about mitochondria**, the powerhouses of human cells, and the roles that mitochondria play in human metabolism and disease as we age.

- We believe these discoveries are the foundation for **an entire new class of mitochondrial-based therapeutic (MBT) drugs**, with potential to significantly slow the progression of major diseases associated with aging, **and increase healthy life span.**

- **We have assembled a leading team** of founders and advisors, together with drug development expertise and capabilities, to exploit these discoveries
- **and have built a pipeline of MBT drug candidates** which we are currently optimizing and targeting for pre-clinical and clinical activities over the next 2-3 years.

Questions?